for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

82.44EUR

Change

-0.79(-0.95%)

Volume

662,562

Today's Range

82.13

 - 

82.96

52 Week Range

67.65

 - 

95.82

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
83.23
Open
82.80
Volume
662,562
3M AVG Volume
50.23
Today's High
82.96
Today's Low
82.13
52 Week High
95.82
52 Week Low
67.65
Shares Out (MIL)
1,253.60
Market Cap (MIL)
104,784.20
Forward P/E
14.08
Dividend (Yield %)
3.78

Next Event

Q4 2020 Sanofi SA Earnings Release

Latest Developments

更多

Sanofi To Name New European API Business Euroapi

Philip Morris Appoints Jorge Insuasty As Chief Life Sciences Officer

Sanofi To Acquire Kymab, Adding Ky1005 To Its Pipeline

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

2.11 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.1K

2018

34.5K

2019

36.1K

2020(E)

36.8K
EPS (EUR)

2017

5.540

2018

5.470

2019

5.990

2020(E)

5.781
Price To Earnings (TTM)
9.34
Price To Sales (TTM)
2.78
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
8.28
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

UPDATE 1-Sanofi's standalone drug ingredients business to be called EUROAPI

The active pharmaceutical ingredients business being carved out by Sanofi will be called EUROAPI, the French drugmaker said on Tuesday, confirming it would decide whether to list the business by next year.

UPDATE 2-Sanofi buys Kymab for up to $1.5 bln to expand in immunotherapy

* Latest deal as Sanofi plays catch up in immunotherapy (Adds details, background)

UPDATE 1-Roche, Sanofi arthritis drugs reduce death rates among sickest COVID-19 patients

* Britain asks doctors to start using them immediately (Adds statement from UK government, bullet points)

Roche, Sanofi arthritis drugs reduce death rates among sickest COVID-19 patients 

Treating critically ill COVID-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday.

UPDATE 5-Sanofi and GSK delay COVID-19 vaccine, marking setback for global fight

* Phase I/II results show low immune response in older adults

GSK says adjuvant volume target of 1 bln doses under review

GlaxoSmithKline said on Friday its goal to produce 1 billion doses of adjuvants - designed to boost COVID-19 vaccine efficacy - in 2021 remained in place but was under review following a development setback with partner Sanofi. .

UPDATE 2-Sanofi believes Europe well prepared to address pandemics

Europe is better prepared than ever to ensure a COVID-19 vaccine reaches the population, Sanofi's chief executive said on Monday.

Sanofi continues to enroll patients for other diseases treatment - CEO

French drugmaker Sanofi continues to enroll patients for the treatment of diseases other than COVID-19 and maintains a 100% capacity to manufacture drugs, its chief executive said on Monday.

Sanofi has narrowed gap vs competitors in development of COVID-19 vaccine - CEO

French drugmaker Sanofi has narrowed the gap against its rivals in the development of a COVID-19 vaccine, its Chief Executive said on Monday.

Activists urge 'Big Pharma' to be transparent on COVID-19 vaccine costs

Activists called on pharmaceutical companies on Thursday to be transparent about the costs and terms of providing COVID-19 vaccines, saying they must be available and affordable for all.

UPDATE 2-Sanofi raises outlook as speciality care and vaccines lift sales

Sanofi raised its 2020 earnings guidance for the second time this year after posting slightly stronger-than-expected third-quarter results on Thursday, helped by growth at its speciality care and vaccines units.

UPDATE 1-Sanofi, GSK to supply vaccine doses to WHO-backed alliance

* COVAX alliance also has deals with AstraZeneca, Novavax (Adds details, background, Paris dateline)

GSK, Sanofi to make 200 mln doses available for COVID-19 vaccine alliance

French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their COVID-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization.

Sanofi reports positive animal test results for potential COVID-19 vaccine

Clinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and U.S. biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals.

Novavax to explore combined influenza/COVID-19 vaccine for use post pandemic

Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.

EXCLUSIVE-AstraZeneca gets partial immunity in low-cost EU vaccine deal

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

Sanofi spokesman says has no role in COVID-19 human challenge trial

Sanofi is not involved in the COVID-19 human challenge trials reported to be launched in Britain and its potential vaccines are not being used in the trials, a spokesman for the French drugmaker said on Wednesday.

UPDATE 3-COVID-19 vaccine makers see EU shield against side-effect claims

* Drugmakers also seek simpler compensation schemes for victims

UPDATE 4-EU pays $384 mln for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

* Many wealthy countries still to join (Adds price paid for deal in second paragraph)

UPDATE 1-Roche studies Ocrevus, experimental drug in bid to defend MS franchise

Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up